Abstract
The aim of this study was to evaluate the cost–effectiveness of ToxNavC , a multivariant genetic test, to screen for DPYD followed by personalized chemotherapy dosing for metastatic breast cancer in the UK compared with no testing followed by standard dose, standard of care. In the main analysis, ToxNav was dominant over standard of care, producing 0.19 additional quality-adjusted life years and savings of £78,000 per patient over a lifetime. The mean additional quality-adjusted life years per person from 1000 simulations was 0.23 savings (95% CI: 0.22–0.24) at £99,000 (95% CI: £95–102,000). Varying input parameters independently by range of 20% was unlikely to change the results in the main analysis. The probabilistic sensitivity analysis showed ∼97% probability of the ToxNav strategy to be dominant.
| Original language | English |
|---|---|
| Pages (from-to) | 339-355 |
| Number of pages | 18 |
| Journal | Personalized Medicine |
| Volume | 20 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1 Jul 2023 |
Bibliographical note
Funding information:The HEcoPerMed project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 824997. S Wordsworth is a co-applicant of a project funded through Genome British Columbia’s GeneSolve program and Illumina and has received travel support from Illumina to attend conferences in MD, USA; Barcelona, Spain; and Basel, Switzerland. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Copyright:
2023 The Authors
